AICAR
Also known as: Acadesine, AICA Ribonucleotide
Molecular Identifiers
Overview
AMPK activator with exercise mimetic properties. Improves endurance and fat oxidation. Adenosine analog that directly activates AMPK kinase.
Small molecule — nucleoside analog (AICA ribonucleoside), not a peptide
Half-life
~2-3 hours
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- Direct activation of AMPK kinase
- Exercise mimetic
- Improvement of endurance capacity
- Increase in fatty acid oxidation
- Improvement of muscle glucose uptake
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 50-150 mg per injection |
| Frequency | 2-3 times per week |
| Timing | Pre-workout |
| Duration | 8-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Hypoglycemia
- Fatigue
- Gastrointestinal discomfort
- Lactic acidosis (high doses)
Reconstitution & Storage
Reconstitution
- Diluent: Bacteriostatic water
- Volume: According to vial concentration
- Slowly inject the diluent along the vial wall
- Gently swirl until fully dissolved
- High doses may require a larger volume of diluent
Storage
- Lyophilized: -20°C or refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on AICAR.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)